KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $51.3 million.

  • Neogenomics' Accumulated Expenses fell 165.63% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.3 million, marking a year-over-year decrease of 165.63%. This contributed to the annual value of $62.4 million for FY2024, which is 1746.02% up from last year.
  • Per Neogenomics' latest filing, its Accumulated Expenses stood at $51.3 million for Q3 2025, which was down 165.63% from $48.6 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Accumulated Expenses ranged from a high of $62.4 million in Q4 2024 and a low of $23.6 million during Q1 2021
  • In the last 5 years, Neogenomics' Accumulated Expenses had a median value of $39.5 million in 2025 and averaged $42.1 million.
  • As far as peak fluctuations go, Neogenomics' Accumulated Expenses soared by 7547.7% in 2021, and later tumbled by 456.56% in 2025.
  • Neogenomics' Accumulated Expenses (Quarter) stood at $38.3 million in 2021, then increased by 4.8% to $40.1 million in 2022, then soared by 32.44% to $53.2 million in 2023, then grew by 17.46% to $62.4 million in 2024, then dropped by 17.84% to $51.3 million in 2025.
  • Its Accumulated Expenses was $51.3 million in Q3 2025, compared to $48.6 million in Q2 2025 and $39.5 million in Q1 2025.